What is HC Wainwright’s Estimate for KROS FY2030 Earnings?

Keros Therapeutics, Inc. (NASDAQ:KROS) – Research analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Keros Therapeutics in a note issued to investors on Thursday, March 5th. HC Wainwright analyst A. Maldonado expects that the company will earn ($2.23) per share for the year. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.74) per share.

KROS has been the subject of a number of other reports. Wall Street Zen cut Keros Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings restated a “sell (d+)” rating on shares of Keros Therapeutics in a report on Monday, December 29th. TD Cowen upgraded Keros Therapeutics to a “hold” rating in a research note on Friday, December 19th. Oppenheimer reaffirmed an “outperform” rating and issued a $27.00 price target (up from $23.00) on shares of Keros Therapeutics in a report on Wednesday, November 12th. Finally, Wells Fargo & Company reduced their price target on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday. Five analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Keros Therapeutics has an average rating of “Hold” and a consensus price target of $21.86.

Keros Therapeutics Stock Down 3.5%

Shares of Keros Therapeutics stock opened at $11.30 on Friday. Keros Therapeutics has a 12-month low of $9.12 and a 12-month high of $22.55. The stock has a market capitalization of $344.31 million, a P/E ratio of 6.21 and a beta of 0.87. The company has a 50-day simple moving average of $17.41 and a 200 day simple moving average of $17.04.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Wednesday, March 4th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.37). Keros Therapeutics had a net margin of 35.65% and a return on equity of 14.25%. The company had revenue of $0.39 million during the quarter, compared to the consensus estimate of $3.66 million. During the same quarter in the prior year, the company posted ($1.14) earnings per share. The company’s revenue for the quarter was down 87.2% on a year-over-year basis.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of KROS. The Manufacturers Life Insurance Company increased its position in shares of Keros Therapeutics by 8.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock valued at $166,000 after buying an additional 988 shares in the last quarter. UBS Group AG lifted its holdings in Keros Therapeutics by 1.1% during the third quarter. UBS Group AG now owns 103,864 shares of the company’s stock worth $1,643,000 after acquiring an additional 1,091 shares in the last quarter. Strs Ohio lifted its holdings in Keros Therapeutics by 3.9% during the fourth quarter. Strs Ohio now owns 29,300 shares of the company’s stock worth $597,000 after acquiring an additional 1,100 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its stake in Keros Therapeutics by 254.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after acquiring an additional 1,166 shares during the period. Finally, Financial Management Professionals Inc. acquired a new position in Keros Therapeutics in the fourth quarter valued at about $29,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.